Cushings Syndrome - Opportunity Assessment and Forecast to 2030
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Cushings Syndrome - Opportunity Assessment and Forecast to 2030
Summary
Cushings Syndrome is a disorder caused by the bodys exposure to an excess of the hormone cortisol. Cortisol affects all tissues and organs in the body, and collectively these effects are known as CS. This disorder can be caused by exogenous sources, primarily the iatrogenic administration of glucocorticoids. Endogenous CS can result from a tumor of the adrenal glands where it produces excess cortisol, elsewhere in the body, ACTH-independent CS, or an ACTH-secreting tumor of the pituitary gland, which stimulates the adrenal glands to produce excess amounts of cortisol (CD).
This report covers 2mm (US and Germany) and provides an Excel-based forecast model for the Cushings Syndrome market through 2030.
Key Highlights
- Forecasts include three countries
- Forecasts cover three time points: base year, 5-year, and 10-year
Scope
- GlobalDatas "Cushings Syndrome - Opportunity Assessment and Forecast to 2030" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global CS market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CS market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Summary
Cushings Syndrome is a disorder caused by the bodys exposure to an excess of the hormone cortisol. Cortisol affects all tissues and organs in the body, and collectively these effects are known as CS. This disorder can be caused by exogenous sources, primarily the iatrogenic administration of glucocorticoids. Endogenous CS can result from a tumor of the adrenal glands where it produces excess cortisol, elsewhere in the body, ACTH-independent CS, or an ACTH-secreting tumor of the pituitary gland, which stimulates the adrenal glands to produce excess amounts of cortisol (CD).
This report covers 2mm (US and Germany) and provides an Excel-based forecast model for the Cushings Syndrome market through 2030.
Key Highlights
- Forecasts include three countries
- Forecasts cover three time points: base year, 5-year, and 10-year
Scope
- GlobalDatas "Cushings Syndrome - Opportunity Assessment and Forecast to 2030" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global CS market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CS market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
TABLE OF CONTENTS
Table of Contents
1 Executive Summary
1.1 Executive Summary
2 Disease Overview
2.1 Overview of Cushings Syndrome
2.2 Cushings Syndrome SWOT Analysis
2.3 Classification of Cushings Syndrome
3 Epidemiology
3.1 Diagnosed Prevalent Cases of CS, 2020-2030
3.2 Diagnosed Prevalent Cases of CS by Specific Type, 2020
3.3 Sources and Methodology
3.4 Diagnosis of Cushings Syndrome - Treatable Population
4 Current Treatment Options
4.1 Treatment Paradigm
4.2 Marketed Products
4.3 Product Profile: Corcept Therapeutics Korlym (mifepristone)
4.4 Product Profile: Recordati SpAs Isturisa (osilodrostat phosphate)
4.5 Product Profile: Recordatii SpAs Signifor (pasireotide)
4.6 Product Profile: Laboratorie HRA Pharma SAS Ketoconazole
4.7 Product Profile: Laboratorie HRA Pharma SAS Metopirone (metyrapone)
4.8 Product Profile: Laboratorie HRA Pharma SAS Lysodren (mitotane)
5 Unmet Needs and Opportunities
5.1 Unmet Needs in CS
5.2 Efficacious Therapies that Target Underlying Causes of CD
5.3 Therapies for Severe CS with Improved Efficacy and Safety
5.4 Physician Awareness of CS Symptomatology
5.5 Improved Referral Systems to Specialists in Secondary Healthcare Settings
5.6 Defined Guidelines for Treatment and Remission
6 Pipeline Assessment
6.1 Cushings Syndrome Pipeline Overview
6.2 Leading Pipeline Agents
6.3 Product Profile: Recorlev
6.4 Product Profile: Relacorilant
6.5 Product Profile: SPI-62
6.6 Pipeline Products - Review Designations
6.7 Cushings Syndrome: Clinical Trials Overview, Phase II/III
7 R&D Strategies
7.1 Trends in Clinical Trial Design in Cushings Syndrome
7.2 Trends in Deal-Making in Cushings Syndrome
8 Market Outlook
8.1 Cushings Syndrome Sales Forecast
8.2 Cushings Syndrome Market Forecast
8.3 Market Drivers and Barriers
9 Appendix
9.1 Primary Research: KOL Information
9.2 About the Authors
10 Contact Us
Figure 1: Summary of Key Findings
1 Executive Summary
1.1 Executive Summary
2 Disease Overview
2.1 Overview of Cushings Syndrome
2.2 Cushings Syndrome SWOT Analysis
2.3 Classification of Cushings Syndrome
3 Epidemiology
3.1 Diagnosed Prevalent Cases of CS, 2020-2030
3.2 Diagnosed Prevalent Cases of CS by Specific Type, 2020
3.3 Sources and Methodology
3.4 Diagnosis of Cushings Syndrome - Treatable Population
4 Current Treatment Options
4.1 Treatment Paradigm
4.2 Marketed Products
4.3 Product Profile: Corcept Therapeutics Korlym (mifepristone)
4.4 Product Profile: Recordati SpAs Isturisa (osilodrostat phosphate)
4.5 Product Profile: Recordatii SpAs Signifor (pasireotide)
4.6 Product Profile: Laboratorie HRA Pharma SAS Ketoconazole
4.7 Product Profile: Laboratorie HRA Pharma SAS Metopirone (metyrapone)
4.8 Product Profile: Laboratorie HRA Pharma SAS Lysodren (mitotane)
5 Unmet Needs and Opportunities
5.1 Unmet Needs in CS
5.2 Efficacious Therapies that Target Underlying Causes of CD
5.3 Therapies for Severe CS with Improved Efficacy and Safety
5.4 Physician Awareness of CS Symptomatology
5.5 Improved Referral Systems to Specialists in Secondary Healthcare Settings
5.6 Defined Guidelines for Treatment and Remission
6 Pipeline Assessment
6.1 Cushings Syndrome Pipeline Overview
6.2 Leading Pipeline Agents
6.3 Product Profile: Recorlev
6.4 Product Profile: Relacorilant
6.5 Product Profile: SPI-62
6.6 Pipeline Products - Review Designations
6.7 Cushings Syndrome: Clinical Trials Overview, Phase II/III
7 R&D Strategies
7.1 Trends in Clinical Trial Design in Cushings Syndrome
7.2 Trends in Deal-Making in Cushings Syndrome
8 Market Outlook
8.1 Cushings Syndrome Sales Forecast
8.2 Cushings Syndrome Market Forecast
8.3 Market Drivers and Barriers
9 Appendix
9.1 Primary Research: KOL Information
9.2 About the Authors
10 Contact Us
List Of Figures
List of FiguresFigure 1: Summary of Key Findings
RELATED REPORTS
Cushings Syndrome (Metabolic Disorders) - Drugs in Development, 2021
Cushings Syndrome (Metabolic Disorders) - Drugs in Development, 2021Cushings Syndrome (Metabolic Disorders) - Drugs in Development, 2021 provides an overview of the Cushings Syndrome pipeline landscape.The report provides comprehensive information
View ReportCushings Syndrome - Market Insight, Epidemiology and Market Forecast - 2028
Cushings Syndrome - Market Insight, Epidemiology and Market Forecast - 2028 report provides a detailed analysis of the Cushings Syndrome epidemiology and market outlook for the 7MM.Markets
View ReportMarfan Syndrome - Global Clinical Trials Review, H2, 2021
Marfan Syndrome - Global Clinical Trials Review, H2, 2021GlobalDatas clinical trial report, Marfan Syndrome - Global Clinical Trials Review, H2, 2021 provides an overview of Marfan Syndrome Clinical trials scenario.
View ReportCarcinoid Syndrome - Pipeline Insight, 2021
DelveInsights, Carcinoid Syndrome - Pipeline Insight, 2021, report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Carcinoid Syndrome pipeline landscape. It covers the pipeline drug profiles, including
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
